Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT
Health Technology Assessment · 2021-01 · 25 (4) · 1-124
DOI: 10.3310/hta25040 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Health Technology Assessment, 2021-01. Verfasst von Anthony P Morrison und 20 weiteren Autor:innen. Beteiligte Einrichtung: Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Antipsychotic Agents, Psychotic Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Department of Health, Chief Scientist Office, Health Technology Assessment programme.
Abstract (Originalsprache)
Background
When psychosis emerges in young people there is a risk of poorer outcomes, and access to evidence-based treatments is paramount. The current evidence base is limited. Antipsychotic medications show only a small benefit over placebo, but young people experience more side effects than adults. There is sparse evidence for psychological intervention. Research is needed to determine the clinical effectiveness and cost-effectiveness of psychological intervention versus antipsychotic medication versus a combined treatment for adolescents with psychosis.
Objectives
The objective of Managing Adolescent first-episode Psychosis: a feasibility Study (MAPS) was to determine the feasibility of conducting a definitive trial to answer the question of clinical effectiveness and cost-effectiveness of these three treatment options.
Design
This was a prospective, randomised, open-blinded, evaluation feasibility trial with a single blind. Participants were allocated 1 : 1 : 1 to receive antipsychotic medication, psychological intervention or a combination of both. A thematic qualitative study explored the acceptability and feasibility of the trial.
Setting
Early intervention in psychosis services and child and adolescent mental health services in Manchester, Oxford, Lancashire, Sussex, Birmingham, Norfolk and Suffolk, and Northumberland, Tyne and Wear.
Participants
People aged 14–18 years experiencing a first episode of psychosis either with an International Classification of Diseases , Tenth Revision, schizophrenia spectrum diagnosis or meeting the entry criteria for early intervention in psychosis who had not received antipsychotic medication or psychological intervention within the last 3 months.
Interventions
Psychological intervention involved up to 26 hours of cognitive–behavioural therapy and six family intervention sessions over 6 months, with up to four booster sessions. Antipsychotic medication was prescribed by the participant’s psychiatrist in line with usual practice. Combined treatment was a combination of psychological intervention and antipsychotic medication. Main outcome measures The primary outcome was feasibility (recruitment, treatment adherence and retention). We used a three-stage progression criterion to determine feasibility. Secondary outcomes were psychosis symptoms, recovery, anxiety and depression, social and educational/occupational functioning, drug and alcohol use, health economics, adverse/metabolic side effects and adverse/serious adverse events.
Results
We recruited 61 out of 90 (67.8%; amber zone) potential participants (psychological intervention, n = 18; antipsychotic medication, n = 22; combined treatment, n = 21). Retention to follow-up was 51 out of 61 participants (83.6%; green zone). In the psychological intervention arm and the combined treatment arm, 32 out of 39 (82.1%) participants received six or more sessions of cognitive–behavioural therapy (green zone). In the combined treatment arm and the antipsychotic medication arm, 28 out of 43 (65.1%) participants received antipsychotic medication for 6 consecutive weeks (amber zone). There were no serious adverse events related to the trial and one related adverse event. Overall, the number of completed secondary outcome measures, including health economics, was small.
Limitations
Medication adherence was determined by clinician report, which can be biased. The response to secondary outcomes was low, including health economics. The small sample size obtained means that the study lacked statistical power and there will be considerable uncertainty regarding estimates of treatment effects.
Conclusions
It is feasible to conduct a trial comparing psychological intervention with antipsychotic medication and a combination treatment in young people with psychosis with some adaptations to the design, including adaptations to collection of health economic data to determine cost-effectiveness. Future work An adequately powered definitive trial is required to provide robust evidence.
Trial registration
Current Controlled Trials ISRCTN80567433. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 25, No. 4. See the NIHR Journals Library website for further project information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK.
- Division of Psychology and Mental Health, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
- Institute for Mental Health, School of Psychology, University of Birmingham, Birmingham, UK.
- Department of Psychiatry, Medical Sciences Division, University of Oxford, Oxford, UK.
- Centre for Human Brain Health, School of Psychology, University of Birmingham, Birmingham, UK.
- Warneford Hospital, Oxford Health NHS Foundation Trust, Oxford, UK.
ORCID-Profile: Anthony P Morrison, Melissa Pyle, Rory Byrne, Matthew Broome, Daniel Freeman, Louise Johns, Anthony James, Nusrat Husain, Richard Whale, Graeme MacLennan, John Norrie, Jemma Hudson, Sarah Peters, Linda Davies, Samantha Bowe, Jo Smith, David Shiers, Emmeline Joyce, Wendy Jones, Chris Hollis, Daniel Maughan
Förderung
- Department of Health
- Chief Scientist Office
- Health Technology Assessment programme
Zitieren
APA
Morrison, A. P., Pyle, M., Byrne, R., Broome, M., Freeman, D., Johns, L., James, A., Husain, N., Whale, R., MacLennan, G., Norrie, J., Hudson, J., Peters, S., Davies, L., Bowe, S., Smith, J., Shiers, D., Joyce, E., Jones, W., …, & Maughan, D. (2021). Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment, 25(4), 1-124. https://doi.org/10.3310/hta25040
Vancouver
Morrison AP, Pyle M, Byrne R, Broome M, Freeman D, Johns L, et al. Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment. 2021;25(4):1-124. doi:10.3310/hta25040
BibTeX
@article{Morrison2021,
author = {Morrison, Anthony P and Pyle, Melissa and Byrne, Rory and Broome, Matthew and Freeman, Daniel and Johns, Louise and James, Anthony and Husain, Nusrat and Whale, Richard and MacLennan, Graeme and Norrie, John and Hudson, Jemma and Peters, Sarah and Davies, Linda and Bowe, Samantha and Smith, Jo and Shiers, David and Joyce, Emmeline and Jones, Wendy and Hollis, Chris and Maughan, Daniel},
title = {Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT},
journal = {Health Technology Assessment},
year = {2021},
volume = {25},
number = {4},
pages = {1--124},
doi = {10.3310/hta25040}
}
EUVIMED